Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | YTHDF2 | Q9Y5A9 | 2/20 | 0.31 |
| ▸ | YTHDF3 | Q7Z739 | 1/20 | 0.31 |
| ▸ | YTHDF1 | Q9BYJ9 | 1/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10351130 | 0.88 | DAO (0.32) | DAOMAPT | |
| SCHEMBL5390017 | 0.87 | — | — | |
| SCHEMBL5386313 | 0.87 | DAO (0.35) | DAOYTHDF2YTHDF3YTHDF1MAP3K14 | |
| SCHEMBL20827756 | 0.87 | MAP3K14 (0.33) | MAP3K14 | |
| SCHEMBL20633691 | 0.82 | MAPT (0.33) | MAPT | |
| SCHEMBL19940735 | 0.82 | YTHDF2 (0.35) | YTHDF2 | |
| SCHEMBL31460270 | 0.77 | CHRNB4 (0.42) | — | |
| SCHEMBL31460244 | 0.77 | CHRNB4 (0.42) | — | |
| SCHEMBL612988 | 0.71 | DAO (0.30) | DAO | |
| SCHEMBL8501155 | 0.71 | DAO (0.30) | DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116813547-A | Method for preparing 3-azabicyclo [3,2,1] octane hydrochloride | 爱斯特（成都）生物制药股份有限公司 | 2023-09-29 | — | — | CN | claimed |
| EP-2376447-B1 | DIPEPTIDYL PEPTIDASE IV INHIBITORS | ORCHID PHARMA LTD (IN) | 2017-08-09 | — | — | EP | claimed |
| US-8466145-B2 | Dipeptidyl peptidase IV inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-06-18 | — | — | US | claimed |
| US-20110257164-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2011-10-20 | — | — | US | claimed |
| EP-2376447-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITORS | Orchid Research Laboratories Limited (IN) | 2011-10-19 | — | — | EP | claimed |
| WO-2010079413-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITORS | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2010-07-15 | — | — | WO | claimed |
| EP-1042315-B1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2004-04-14 | — | — | EP | claimed |
| EP-1042315-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | Klinge Pharma GmbH (DE) | 2000-10-11 | — | — | EP | claimed |
| WO-1999031087-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | claimed |
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. | 2025-06-26 | — | — | US | disclosed |
| WO-2023141570-A9 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-116813547-A | Method for preparing 3-azabicyclo [3,2,1] octane hydrochloride | 爱斯特（成都）生物制药股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023141570-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023141570-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| EP-1042315-B1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2004-04-14 | — | — | EP | disclosed |
| EP-1042315-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | Klinge Pharma GmbH (DE) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999031087-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
| EP-0309544-A1 | PSYCHOTROPIC BICYCLIC IMIDES. | AMERICAN HOME PROD (US) | 1989-04-05 | — | — | EP | disclosed |
| WO-1988007530-A1 | PSYCHOTROPIC BICYCLIC IMIDES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-10-06 | — | — | WO | disclosed |
| US-4748240-A | Psychotropic bicyclic imides | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257164-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITORS | DPP4, DPP7, DPP3 | DAO 535/4885YTHDF2 4650/4885YTHDF3 4477/4885 |
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | KRAS, MDM2, VHL | DAO 1112/4885YTHDF2 3772/4885YTHDF3 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.